Chicago Capital LLC Reduces Stake in DexCom, Inc.

The investment firm sold over 344,000 shares of the medical device company in Q4 2025.

Apr. 18, 2026 at 7:37am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of the internal components and mechanics of a continuous glucose monitoring device, rendered in a stark, industrial black-and-white style that evokes the photographic style of Margaret Bourke-White, serving as a conceptual metaphor for the financial and technological forces shaping the medical device industry.The intricate inner workings of a DexCom CGM device, a critical technology for diabetes management, reflect the complex financial landscape surrounding the medical device industry.San Diego Today

Chicago Capital LLC, an investment management firm, reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 38.8% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 544,602 shares of the medical device company's stock, down from 889,486 shares held previously.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, a critical technology for diabetes management. The reduction in Chicago Capital's position could signal a shift in investor sentiment around the stock or the broader medical device industry.

The details

In its 13F filing, Chicago Capital reported selling 344,884 shares of DexCom stock during the fourth quarter. The firm now owns approximately 0.14% of DexCom's outstanding shares, valued at $36.1 million as of the end of 2025.

  • Chicago Capital filed its 13F report for the fourth quarter of 2025 on April 18, 2026.
  • The firm reduced its DexCom holdings during the three-month period ending December 31, 2025.

The players

Chicago Capital LLC

An investment management firm that previously held a sizable position in medical device company DexCom, Inc.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Chicago Capital's DexCom holdings could signal a broader shift in investor sentiment around the medical device industry, particularly as it relates to diabetes management technologies. However, DexCom remains a leader in the CGM market, and its long-term growth prospects continue to be closely watched by analysts.